| Metric | Value | Change |
|---|---|---|
| Revenue | 104.31 Cr | |
| Total Income | 106.38 Cr | |
| Expenditure | 95.85 Cr | |
| PBT | 10.60 Cr | |
| Net Profit | 8.07 Cr | |
| OPM | — | |
| NPM | 7.59% | |
| EPS | 0.67 |
43% growth, margin pressure; field force investment cycle ahead
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Company met its Q1 delivery (104.3 Cr revenue, 8.1 Cr PAT). 20–25% FY27 guide is new forward guidance, not a change to prior numbers; appears credible but conservative.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 delivered 43% revenue growth with solid 25% PAT growth, and capacity utilization jumped to 47%, signaling operational traction. However, EBITDA margin compressed 250 bps (13.8% → 11.3%) due to raw material and freight cost inflation tied to the West Asia crisis, partially offset by 10–15% MRP increases. Management is credible and transparent about headwinds and mitigation, but near-term margin recovery is unproven; field force scale investments require 2–3 quarter productivity ramp. FY27 guidance of 20–25% growth is conservative relative to Q1, reflecting seasonal patterns in prior years. Upside exists as margins recover and field force pays off; downside if raw material costs persist or order flow slows.
₹104.3 Cr
Revenue · +43.2% YoY₹8.1 Cr
Reported PAT · +25.1% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
43.2% YoY revenue growth, volume-driven
METRevenue 104.3 Cr vs 72.9 Cr Q1 FY26 = 43.2% growth; volume 25–40% YoY
PAT grew 25.1% YoY to 8.1 Cr
METPAT 8.1 Cr vs 6.5 Cr Q1 FY26 = 25.1% growth; delivered
EBITDA margin 11.3%, reflects product mix and growth investments
METEBITDA 11.8 Cr / 104.3 revenue = 11.3%; prior year 13.8%. 250 bps compression
Gross margin pressure from West Asia raw material cost inflation
METGross profit growth 34.1% vs revenue 43.2%; gross margin contracted 3% YoY. Management cited whey protein cost rises
Capacity utilization now 47%, exceeding prior expectations of 35–40%
METBlended 40–47% cited. Nashik 55–60%, Chennai 25–30%, Tuticorin 35–40%. Exceeds prior 35–40% guide
Earnings quality
What changed since the last call
EBITDA margin: 13.8% → 11.3%
DowngradeQ1 FY27 margin fell 250 bps YoY. Raw material cost surge (West Asia whey protein inflation) and freight hikes blamed; field force scale (+50% headcount) added 150–200 bps opex drag. MRP increases 10–15% to recover.
Capacity utilization: 30% → 47%
UpgradeBlended capacity jumped 17 ppts vs prior year. Nashik 55–60% (tight), Chennai 25–30% (headroom), Tuticorin 35–40%. Exceeds prior 35–40% target.
Field force investment: new
New50% increase in field force headcount to expand Tier 2/Tier 3 reach. Opex impact visible in Q1; productivity expected by Q3–Q4.
The Q&A
Analysts pressed hard on margin compression vs 43% revenue growth; management candid, cited geopolitical raw material inflation and acknowledged freight pressure. Held firm on 20–25% FY27 growth despite Q1's 43%, credibly attributed to seasonality. One analyst skeptical on slowdown risk; management countered with ₹100 Cr Q2 order book and historical seasonal patterns.
Export concentration — Sparsh Bedmutha, Perpetual Capital Advisors
AnsweredTop 5 countries = 25–40% of exports. West Asia < 20% of total exports. Diversified footprint across 70+ countries limits single-market risk.
Capacity utilization — Sparsh Bedmutha, Perpetual Capital Advisors
AnsweredBlended 47%. Premix >50% of revenue drives utilization; branded growing. Volume growth 47% YoY this quarter.
FY27 growth guidance — Sparsh Bedmutha, Perpetual Capital Advisors
Answered20–25% growth range, same as last year's trajectory. Conservative approach maintaining consistency.
Largest segment opportunity — Mayuresh Raut, individual investor
AnsweredBranded segment is fastest-growing, 28% YoY this quarter. Share grew from 18% to 30% of revenue over years.
Revenue mix evolution — Mayuresh Raut, individual investor
PartialBranded 28%, premix 62%, ESG 10% this quarter. All segments growing; branded will show 'definite growth' similar to last year trajectory. Premix remains backbone.
B2C growth to 35% — Mayuresh Raut, individual investor
AnsweredExpect to reach 35% mark in next couple of years.
Slowdown risk — Akhilesh, Ampersand Capital
AnsweredQ2 strongly supported by ₹100 Cr order book. Historically Q1–Q2 gather momentum; Q3–Q4 see main growth surge. No slowdown expected.
Gross margin contraction — Akhilesh, Ampersand Capital
AnsweredWest Asia crisis: critical raw materials (premix, branded) cost spike. Taking call to pass costs to customers 10–15% MRP increase. Steps in place to normalize Q2–Q3.
Price vs volume split — Akhilesh, Ampersand Capital
AnsweredVolume growth 25–40% YoY across premix and branded. Price not main driver; selective MRP increases (10–15%) on branded due to raw material cost.
Other expenses spike — Abhishek Maheshwari, Skyridge Fund Managers
AnsweredFreight cost up due to West Asia geopolitical impact. Strategic investment in selling/distribution, field force >50% increase. Viewed as investment; will pay off in coming quarters.
Operating cash flow — Varun, individual investor
AnsweredOperating cash flow improved vs prior year Q1. Cash conversion issue from FY26 resolved; large ESG/premix shipments drove recovery and receivable collection.
Inventory and receivables — Varun, individual investor
AnsweredInventory days 142 (vs 130 prior) due to order book positions and strategic build ahead of price rises. No major credit term changes.
FY27 capex — Varun, individual investor
AnsweredNashik premix facility redevelopment: ₹25–30 Cr capex over 1–1.5 years. 70% funded via long-term bank borrowing; limited impact on operating cash flow.
Order book visibility — Urvija Shah, Isha Securities
Answered₹100 Cr order book, executing Q2 and partly Q3. 70–75% premix/ESG, rest branded.
Capacity utilization by facility — Urvija Shah, Isha Securities
AnsweredBlended 40–47%. Premix 3 facilities, all showing growth. Branded also growing. Packaging mix differs (25kg bags premix vs 1g–1kg sachets branded), so blended metric can mask segment-level variation.
ESG order pipeline — Mira Mittal, individual investor
Answered₹75–100 Cr for the year (ESG pipeline). Good order book from national governments continuing production.
Raw material sourcing — Kamal Jeswani, UFirst Capital
Answered25–30% sourced internationally, majority domestic. Whey proteins saw cost upsurge; some vitamins stable. No plant-based nutrition plans in immediate future.
International growth — Poshita Shetty, individual investor
AnsweredGrowth in Central Asia and Africa. Looking at newer geographies: Europe and North America.
Facility-level capacity — Manasvini Mukherjee, Oracle Investments
AnsweredNashik 55–60%, Chennai 25–30%, Tuticorin 35–40%, Uzbekistan modest (Q2–Q3 delivery orders only).
Growth constraints — Yash Parkar, Patel Investments
AnsweredCapacity sufficient for 2–3 years. Working capital well-managed. Distribution expanding Tier 2–3 with field force scale; 2–3 quarters to productivity. No binding constraints seen.
D2C channel evolution — Yash Parkar, Patel Investments
AnsweredStrengthening e-commerce via social media, influencers (fitness, mom), Amazon/Flipkart promotions, e-pharmacies. 85% orders delivered in 24 hours. Digital business 'bound to grow by leaps and bounds.' No near-term margin pressure noted.
Margin compression drivers — Yash Parkar, Patel Investments
AnsweredBranded +22%, premix +55%, ESG +42% YoY volume growth. Pressure predominantly gross margin issue (geopolitical raw material cost). MRP increases 10–15% to ease pressure next 2 quarters. Freight cost up (West Asia). Field force investment (+50% headcount) depressing bottom line but expected to add value and revenue growth in coming quarters.
Guidance
FY27 revenue growth 20–25%
MediumConservative vs Q1's 43%. Management cites seasonality: Q1–Q2 momentum-build, Q3–Q4 main growth. Historical quarterly data supporting pattern; ₹100 Cr Q2 order book underpins near-term confidence.
EBITDA margin recovery through MRP pass-through and field force productivity
MediumMRP increases 10–15% on branded products effective Q2 onwards to recover gross margin. Field force +50% headcount to drive operating leverage in Q3–Q4 and beyond (2–3 quarter productivity ramp).
Segment margins: branded 60–68%, premix 35–40%, ESG 25–30% (from prior call)
LowNot restated in Q1 call; inferred from prior guidance. Branded margin pressure evident (investment phase). Premix/ESG under raw material cost pressure.
FY27–FY28 capex: ₹25–30 Cr for Nashik premix facility redevelopment
High70% bank-funded (₹17.5–21 Cr debt), limiting cash impact. Expected to modernize capacity and support future growth.
Risks the call surfaced
Raw material cost inflation
HighWest Asia crisis drove whey protein and other critical raw material costs up, compressing gross margin by 3% YoY. MRP pass-through (10–15%) is management's lever but timing and customer acceptance uncertain.
Field force productivity
Medium50% increase in field force headcount (hired May–June 2026) to expand Tier 2/Tier 3 reach. Significant opex drag in Q1; management expects 2–3 quarter productivity lag before operating leverage kicks in. Delay or underperformance could persist margin pressure.
ESG order flow volatility
MediumESG segment (10% of revenue) is tender-based with quarterly order flow variability. Annual pipeline ₹75–100 Cr provides visibility but concentration among national government orders (UNICEF, UN agencies) creates execution risk.
Freight cost pressure
MediumWest Asia geopolitical situation increased freight costs, adding pressure to PAT. Exports represent ~30% of revenue; cost volatility directly impacts profitability if not passed through.
Capacity expansion execution
Low₹25–30 Cr Nashik premix facility redevelopment planned over 1–1.5 years. 70% debt-funded but project complexity and cost inflation risks (raw material, labor) could delay commissioning or increase debt burden.
Management
Score 7/10. Clear and transparent on challenges. Management candid about West Asia raw material spike, freight costs, and field force investment impact. Provided granular facility-level capacity data (Nashik 55–60%, Chennai 25–30%) and segment-wise growth breakdowns unprompted. Acknowledged margin compression and outlined concrete mitigation (MRP 10–15% increases, strategic inventory buildup). Q1 delivered on numbers: 104.3 Cr revenue (43.2% growth) and 8.1 Cr PAT (25.1% growth) vs stated results. Capacity utilization exceeded prior 35–40% target, reaching 47%. Order book ₹100 Cr provides Q2–Q3 visibility. First quarterly results post-IPO; on-time delivery and credible guidance support track record build.
1 · Q2 FY27
MRP pass-through of 10–15% materializes in gross margin; Q2 order book (₹100 Cr) executes
2 · Q3–Q4 FY27
Field force productivity ramp; seasonal revenue acceleration (historical H2 > H1)
3 · FY28 onward
Nashik premix facility redevelopment (₹25–30 Cr capex, 70% bank-funded) comes online with modernized capacity
Upside exists as margins recover and field force pays off; downside if raw material costs persist or order flow slows.
Volume Juggernaut, Margin Puzzle
Hexagon Nutrition delivered 43% revenue growth in Q1 FY27, but PAT grew only 25% and EBITDA margin compressed 250 basis points. The quarter exposes an operating leverage challenge: growth without the margin expansion investors banked on.
On the revenue line it's a blowout — ₹104.3 crore represents 43% YoY growth on strong volume momentum across premix, branded, and ESG. But PAT grew only 25%, and EBITDA margin fell to 11.3% from 13.8%. That gap — rapid growth that didn't deliver expected margin expansion — is the story of Q1 FY27. It's also a puzzle: textbook inputs (volume, capacity), but textbook operating leverage hasn't shown up. Management's explanation is credible but unproven. Whether this quarter is an investment phase (margins to recover next quarter) or a warning sign (structural margin pressure) shapes the outlook.
43.2%
₹104.3 Cr vs ₹72.9 Cr prior year
25.1%
₹8.1 Cr vs ₹6.5 Cr prior year
11.3%
−250 bps vs 13.8% prior
43.9%
−290 bps vs 46.8% prior
What didn't show up: where the margin went
Revenue grew 43%, but gross profit only grew 34% (₹45.8 Cr vs ₹34.1 Cr prior year). Gross margin fell 290 basis points, compressed by West Asia geopolitical raw material cost inflation — whey proteins and other premix/branded inputs spiked. Management's read: critical feedstocks sourced internationally (25–30% of materials) saw cost hikes; the company is taking a calculated call to pass 10–15% MRP increases to customers in Q2–Q3, betting customer stickiness will hold.
Operating expenses also grew faster than revenue. Field force headcount jumped 50% (hired May–June 2026) to expand Tier 2/Tier 3 reach; the payoff is expected in Q3–Q4 once new hires hit full productivity (a 2–3 quarter ramp). Freight costs also rose due to geopolitical disruption. The result: EBITDA fell 250 bps despite 43% topline growth. For a scaled nutrition platform at 47% capacity utilization, this is a red flag, not a speed bump — it signals that raw cost inflation and strategic investments are eating profitability right now.
The major reason is the West Asia crisis where we have seen few of our critical raw materials in our segments in premix as well as branded has seen a rise in the cost... we are taking a call to pass the cost to customers. We expect hopefully to mitigate, if not fully recover, the margin impact in Q2 and Q3.
Management's claims vs. what holds up
43.2% YoY revenue growth, volume-driven
Revenue ₹104.3 Cr vs ₹72.9 Cr prior year Q1 = 43.2%. Volume growth cited 25–40% across segments. Price component minimal (selective MRP increases just starting).
Supported
PAT grew 25.1% YoY to ₹8.1 Cr
PAT ₹8.1 Cr vs ₹6.5 Cr prior = 25.1% growth. Delivered as reported.
Supported
Capacity utilization jumped to 47% (from ~35–40% prior)
Blended 40–47% cited. Nashik 55–60% (tight), Chennai 25–30%, Tuticorin 35–40%. Exceeds prior guidance.
Supported
Gross margin pressure is West Asia raw material inflation, not mix or operational derating
Gross profit grew 34% vs revenue 43%; gross margin fell 290 bps. Management cited whey protein and critical raw material cost spikes. Mix shift is actually favorable (branded +28% mix, premix +55% volume).
Supported
FY27 guidance of 20–25% growth is conservative and credible; seasonality expected to accelerate Q3–Q4
20–25% guidance is new forward guidance for FY27 (same range as prior year). Q1–Q2 historically slower, Q3–Q4 faster. ₹100 Cr Q2 order book supports near-term confidence. But historical pattern not explicitly shown.
Plausible but unproven
Field force investment is a 2–3 quarter ramp, then will add value
50% headcount increase hired May–June 2026. Opex drag visible in Q1. No ramp data yet; management confidence is credible but contingent on execution.
Supported in principle; unproven in execution
What changed on this call
EBITDA margin: 13.8% → 11.3% (−250 bps YoY)
Capacity utilization: ~30% → 47% YoY (exceeds prior 35–40% target)
Branded revenue mix: 28% now, path to 35% in couple of years
Field force investment: 50% headcount increase (May–June onboard), newly visible opex drag
Gross margin contraction: 3% YoY, blamed on West Asia raw material inflation, not demand
ESG order pipeline: ₹75–100 Cr annually for FY27, tender-based but with government order visibility
The bull-bear ledger
Revenue growth 43% YoY with volume-driven mix; 25–40% volume growth signals demand strength, not price tricks
Capacity utilization 47% (Nashik 55–60% tight) shows deployment excellence; headroom at Chennai (25–30%) and Tuticorin (35–40%) for future scale
Branded segment 28% mix, targeting 35%; higher-margin clinical/wellness products scaling (28% YoY growth)
Order book visibility: ₹100 Cr in Q2 and ESG pipeline ₹75–100 Cr annually support near-to-medium term topline confidence
Field force investment is strategic and likely accretive; 2–3 quarter productivity ramp is standard for sales-force scaling
Promoter-backed (64% ownership); insider buying near lows (NAVRATRI at ₹49–54 range in July) suggests confidence
PAT growth (25%) lagging revenue growth (43%) is a reversal of operating leverage; investors expected the opposite
Gross margin compression 290 bps despite favorable mix (branded +28%) shows raw input cost is a headwind, not temporary
MRP pass-through (10–15%) is management's lever but unproven; customer acceptance risk if competitors hold prices
FY27 guidance 20–25% growth is conservative vs Q1's 43%; limited upside surprise room; market already down 18.67% from ATH
West Asia geopolitical risk persists; raw material costs and freight volatility remain high
FII ownership minimal (0.29%); institutional investors weak, possibly skeptical on margin recovery or valuation at growth rates
ESG business tender-based and lumpy; ₹75–100 Cr is guidance, not contracted
Risks, ranked by how much they should concern a holder
Gross margin doesn't recover if raw material costs stay elevated or MRP pass-through fails
HighGross margin is 44% of revenue. A 290 bps permanent loss (vs 46.8% prior) is ₹3 Cr PAT drag annually on ₹100 Cr revenue. If MRP increases don't stick with customers or competitors hold prices, EBITDA margin stays at 11% (vs prior 14%), a 30% earnings cut.
Field force productivity ramp extends beyond 2–3 quarters or delivers lower ROI
Medium50% headcount added (May–June 2026) is a significant opex commitment. If Tier 2/3 expansion underperforms or productivity lags, operating leverage delays and PAT growth stalls through H2 FY27.
West Asia geopolitical crisis persists; raw material supply tightens or freight costs spike further
MediumCompany sources 25–30% of materials internationally; whey proteins saw cost spikes. If supply disruption worsens, margin headwinds deepen and MRP increases must be larger (risking volume loss).
FY27 guidance 20–25% growth undershoots due to seasonality not materializing or order book execution delays
MediumGuidance is conservative relative to Q1's 43%, but if H2 FY27 doesn't see historical seasonal acceleration, stock faces guidance miss and re-rating downside.
ESG order book lumpy or pipeline ₹75–100 Cr slips due to government budget cycles or program delays
Low-MediumESG is 10% of revenue and tender-based. A ₹20–30 Cr execution miss would be material to FY27 growth, but diversified order base (national programs, UNICEF, UN agencies) limits single-order risk.
How the street is positioned (and what it means)
The stock opened the quarter at ₹64.56 on Aug 12 2026 and posted a day-1 pop of +0.46% on the result, holding 100% delivery. By day 3, that pop faded to −1.72%, and the stock now trades at ₹63.45 — near the open, down 18.67% from its all-time high of ₹78.02. The market gave the result a shrug, not a cheer. This tells two things: (1) growth investors already had high expectations and were underwhelmed by the margin compression; (2) the street is pricing in near-term margin recovery risk.
Ownership tells the same story. Promoters hold a tight 64.29%, showing long-term alignment and no insider panic. But FII ownership is negligible at 0.29% — foreign growth investors have essentially passed. DII holdings are modest at 6.43%. This is a domestic, founder-led story, not an institutional one. The absence of FII capital is notable: a company growing 43% with capacity traction should attract offshore money, but instead it's raising questions on valuation relative to margin recovery risk.
Bulk/block activity shows NAVRATRI SHARE TRADING (a fund/trader entity) buying near the lows in July (₹49–54 range) after earlier sales at ₹50–51. This looks like tactical accumulation rather than insider distress. No promoter selling near the highs — a positive signal.
The debate
What to watch next
1 · Q2 gross margin recovery
Did the 10–15% MRP increases on branded products materialize and stick? Gross margin should rise from 43.9% (Q1) toward 45%+ if pass-through worked. A miss here = margin recovery narrative fails, stock likely re-rates lower.
2 · Q3 EBITDA margin and field force productivity
New field-force hires (May–June 2026) should turn productive by Q3. EBITDA margin should improve from 11.3% toward 12%+ if operating leverage kicks in. Lack of productivity = margin stays depressed, PAT growth disappoints.
3 · Q2–Q3 order book execution and ESG pipeline traction
₹100 Cr Q2 order book and ₹75–100 Cr ESG pipeline must execute to validate the 20–25% FY27 growth guidance. If either slips, topline growth slows and margin pressure from opex (field force) becomes permanent.
Hexagon Nutrition's Q1 FY27 is a tale of operational traction (volume, capacity, order book) tempered by near-term margin recovery risk (raw materials, freight, field force investment). The company's story is credible, management is transparent, and the order book is strong. But the fundamental challenge is real: PAT growth (25%) lagging revenue growth (43%) is a step backward for a manufacturing platform. The verdict is steady execution, not a step-change. The single number to track from here is organic EBITDA margin — if it recovers to 13%+ in Q2–Q3, the street will re-rate the stock upward; if it stays at 11–12%, the stock has limited upside from current levels. Hold until Q2 results provide clarity on MRP pass-through and field force productivity.